This systematic review examined pivotal phase II and III randomized controlled trials in urinary tract oncology. These trials were either presented at major conferences in 2025 or published that same year. The studies focused on patients with bladder, kidney, prostate, testicular, and penile cancers who received novel therapeutic strategies.
The main finding indicates that 2025 evidence establishes multiple new standards of care across these cancer types. This progress emphasizes the importance of biomarker-driven strategies, the integration of immunotherapy, understanding novel resistance mechanisms, and optimizing treatment approaches for these specific malignancies.
Readers should understand that while this review provides an evidence-based framework for updating clinical guidelines, specific numerical results and detailed safety data were not available for extraction. The review notes persistent challenges and future research needs. This work helps establish new standards but does not provide specific effect sizes or absolute numbers for individual treatments.
